Results 141 to 150 of about 3,979 (188)
Some of the next articles are maybe not open access.
Journal of Urology, 2000
Agonistic analogs of luteinizing hormone-releasing hormone (LHRH) are widely used for therapy of advanced prostate cancer based upon their ability to suppress testosterone secretion in patients. Various studies also indicate that LHRH analogs might have direct inhibitory effects on prostate tumors mediated by specific LHRH receptors.
G, Halmos +4 more
openaire +2 more sources
Agonistic analogs of luteinizing hormone-releasing hormone (LHRH) are widely used for therapy of advanced prostate cancer based upon their ability to suppress testosterone secretion in patients. Various studies also indicate that LHRH analogs might have direct inhibitory effects on prostate tumors mediated by specific LHRH receptors.
G, Halmos +4 more
openaire +2 more sources
Enhanced Anti-Tumoral Activity of Methotrexate-Human Serum Albumin Conjugated Nanoparticles by Targeting with Luteinizing Hormone-Releasing Hormone (LHRH) Peptide [PDF]
Active targeting could increase the efficacy of anticancer drugs. Methotrexate-human serum albumin (MTX-HSA) conjugates, functionalized by luteinizing hormone-releasing hormone (LHRH) as targeting moieties, with the aim of specifically targeting the ...
Azade Taheri +2 more
exaly +2 more sources
Characterization and autoradiographic localization of LHRH receptors in the rat brain
Synapse, 1987AbstractLuteinizing hormone‐releasing hormone (LHRH) is distributed in several extrahypothalamic areas, suggesting that it might act as a neurotransmitter or neuromodulator in the central nervous system. This study was undertaken to characterize and localize LHRH receptors in the rat brain by using slide‐mounted frozen sections.
M, Badr, G, Pelletier
openaire +2 more sources
LHRH Receptor Targeted Therapy for Breast Cancer
2008Breast cancer remains the most common cancer among women, with an estimated 212,920 new cases and 40,970 deaths in the United States in 2006. The present work extends the studies of nanoparticles targeted to the luteinizing hormone-releasing hormone (LHRH) receptor which is overexpressed in breast, ovarian, endometrial and prostate cancer cells.
S S, Kakar +4 more
openaire +2 more sources
Modulation of hippocampal LHRH receptors by sex steroids in the rat
Peptides, 1988The modulation of brain LHRH receptors by sex steroids was assessed in the female rat hippocampus using in vitro autoradiography and iodinated [D-Ser (TBU)6, des-Gly-NH2(10)]LHRH ethylamide as the radioligand. As evaluated by optical densitometry, the density of hippocampal LHRH receptors was increased by castration.
Badr M +2 more
openaire +3 more sources
LHRH receptor expression in sarcomas of bone and soft tissue
Hormone Molecular Biology and Clinical Investigation, 2016Abstract Aim: Luteinizing hormone releasing hormone (LHRH) is a neurohormone, secreted by the hypothalamus, which regulates the secretion of gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the pituitary.
Chenthuran, Deivaraju +4 more
openaire +2 more sources
Receptor-mediated internalization of LHRH antagonists by pituitary cells
Molecular and Cellular Endocrinology, 1983A fluorescently labeled antagonist of luteinizing hormone releasing hormone (LHRH), D-pGlu-D-Phe-D-Trp-Ser-Tyr-D-Lys6-(tetramethylrhodamine)-Leu-Arg-Pro-Gly-NH2, was prepared. This peptide retained high-affinity binding to the LHRH receptor of pituitary plasma membrane preparations.
E, Hazum +5 more
openaire +2 more sources
Effects of an LHRH agonist and gonadotropins on testicular prolactin receptors
Peptides, 1982Effects of administration of the LHRH agonist D-Leu6-LHRH ethylamide (LHRH-A), gonadotropin (PMS), and their interaction on testicular prolactin (PRL) receptor levels were investigated in rats. LHRH-A (2 micrograms/100 g body wt.) or saline was injected SC daily, and PMS (5 IU) injected every other day.
J B, Fishback +2 more
openaire +2 more sources
Neuroendocrinology, 2008
Hypophyseal and ovarian receptors for the neurohormone LHRH (LHRH-R) have been measured in young (3–4 months), middle-aged (8–11 months), constant estrous (CE, 10–14 months) and pseudopregnant (PR, 16–18 months) rats in order to study whether changes in hypothalamic and/or peripheral LHRH-like peptide production might precede and/or accompany the onset
MARCHETTI, Bianca Maria, CIONI, Matteo
openaire +3 more sources
Hypophyseal and ovarian receptors for the neurohormone LHRH (LHRH-R) have been measured in young (3–4 months), middle-aged (8–11 months), constant estrous (CE, 10–14 months) and pseudopregnant (PR, 16–18 months) rats in order to study whether changes in hypothalamic and/or peripheral LHRH-like peptide production might precede and/or accompany the onset
MARCHETTI, Bianca Maria, CIONI, Matteo
openaire +3 more sources
Cancer Research, 2013
Abstract Background For drug-targeting aimed at the treatment of LHRH receptor overexpressing cancers the LHRH receptor agonistic peptide D-Lys6-LHRH has been conjugated to the novel highly cytotoxic natural compound Disorazol Z.
Babette Aicher +10 more
openaire +1 more source
Abstract Background For drug-targeting aimed at the treatment of LHRH receptor overexpressing cancers the LHRH receptor agonistic peptide D-Lys6-LHRH has been conjugated to the novel highly cytotoxic natural compound Disorazol Z.
Babette Aicher +10 more
openaire +1 more source

